Cargando…
A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy
INTRODUCTION: Ex vivo organ cultures (EVOC) were recently optimized to sustain cancer tissue for 5 days with its complete microenvironment. We examined the ability of an EVOC platform to predict patient response to cancer therapy. METHODS: A multicenter, prospective, single-arm observational trial....
Autores principales: | Golan, Shay, Bar, Vered, Salpeter, Seth J., Neev, Guy, Creiderman, German, Kedar, Daniel, Aharon, Sara, Turovsky, Lubov, Zundelevich, Adi, Shahar, Hamutal, Shapira, Hagit, Mallel, Giuseppe, Stossel, Erez, Gavert, Nancy, Straussman, Ravid, Dotan, Zohar, Berger, Raanan, Stossel, Chani, Golan, Talia, Halperin, Sharon, Leibovici, Dan, Breuer, Shani, Rottenberg, Yakir, Applebaum, Liat, Hubert, Ayala, Nechushtan, Hovav, Peretz, Tamar, Zick, Aviad, Chertin, Boris, Koulikov, Dmitry, Sonnenblick, Amir, Rosenbaum, Eli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569691/ https://www.ncbi.nlm.nih.gov/pubmed/37840996 http://dx.doi.org/10.3389/fmed.2023.1221484 |
Ejemplares similares
-
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
por: Stossel, Chani, et al.
Publicado: (2023) -
Temporal trends of geographic variation in mortality following cancer diagnosis: a population-based study
por: Rottenberg, Yakir, et al.
Publicado: (2019) -
Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations
por: Arnon, Johnathan, et al.
Publicado: (2023) -
Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
por: Zick, Aviad, et al.
Publicado: (2017) -
Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer
por: Deshet-Unger, Naamit, et al.
Publicado: (2022)